Admission to Trading on Euronext Brussels – About Your Online Magazine


THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ALL OR IN PART, TO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS ILLEGAL TO DISTRIBUTE THIS ANNOUNCEMENT

PUBLICATION IN APPLICATION OF ARTICLE 15 OF THE BELGIAN TRANSPARENCY LAW OF MAY 2, 2007

Acacia Pharma Group plc

Admission to trading on Euronext Brussels

Cambridge, UK and Indianapolis, USA – February 23, 2021, 08:00 CET: Acacia Pharma Group plc (“Acacia Pharma“or”Company”) (EURONEXT: ACPH), a biopharmaceutical company in the commercial phase focused on the development and commercialization of new products to improve the care of patients undergoing severe medical treatments, such as surgery, invasive procedures or chemotherapy, announces that, following the announcements of February 18, 2021 and February 19, 2021 in relation to the placement of new common shares in the Company (the “New Common Shares“) through an accelerated bookbuild offering (the“Placing”), 10,000,000 New Common Shares were issued and admitted to trading on the regulated market of Euronext Brussels.

New Common Shares issued pursuant to the Placement have the same rights and benefits as, and classify passi passu in all respects with the existing Common Shares.

After the issue of the New Common Shares, on February 23, 2021, the Company’s total issued share capital amounts to £ 1,993,789.02, represented by 99,689,451 common shares with one vote per share. The Company has no common shares in treasury and has not issued any other securities with voting rights. Therefore, the total number of voting rights in the Company is 99,689,451. This number represents the denominator for the purposes of notifications under the transparency regulations.

Based on this information, the Company’s shareholders can check whether they are above or below one of the limits of 5%, 10%, 15%, 20% and so on, in multiples of five, of the total voting rights, and whether there is, therefore, an obligation to disclose that they have reached, exceeded or fallen below any of these limits under the Belgian Transparency Act of 2 May 2007. Notifications of important entries must be sent by email for Acacia Pharma, to the attention of Ali Elsley in AliElsley@acaciapharma.com, as well as for the Belgian Financial Services and Markets Authority (FSMA), in trp.fin@fsma.be.

The Company has a total of 2,437,960 outstanding options and 2,861,500 Units of Restricted Shares, for the benefit of current and former employees and managers of the group, granting the right to subscribe a maximum total of 5,299,460 new common shares , each conferring a voting right.

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

American investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

Acacia Pharma Group plc
The Officers ’Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products that aim to improve the care of patients undergoing significant treatments, such as surgeries, other invasive procedures or cancer chemotherapy. The company identified important and commercially attractive unmet needs in those areas that its product portfolio aims to meet.

Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is marketed in the USA for the treatment of postoperative nausea and vomiting (PONV).

BYFAVO ™ (remimazolam) for injection, a very fast onset / compensation IV benzodiazepine sedative has been approved and launched in the USA for use during adult invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is licensed by Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy-induced nausea and vomiting (CINV), has successfully completed a proof of concept and a Phase 2 study of dose variation in patients receiving highly emetogenic chemotherapy.

Acacia Pharma is headquartered in the United States in Indianapolis, IN and its R&D operations are centralized in Cambridge, United Kingdom. The company is listed on the Euronext Brussels stock exchange under the ISIN code GB00BYWF9Y76 and the symbol ACPH.

www.acaciapharma.com

Important information

These materials are not for release, publication or distribution, directly or indirectly, in whole or in part, to or within the United States (including its territories and possessions, any State of the United States and the District of Columbia). These materials are for informational purposes only and do not constitute or form part of any offer or request to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act“), or under the laws of the securities of any state or other jurisdiction of the United States. The securities mentioned herein may not be offered or sold in the United States, except in accordance with an exemption from US Securities registration requirements. Act and in compliance with all applicable securities laws of any state or other jurisdiction in the United States There will be no public offering of securities in the United States.

This press release (and the information contained herein) is not intended to be released, published or distributed, directly or indirectly, in whole or in part, in Australia, Canada, Japan or South Africa or any other jurisdiction where doing so may constitute a violation of the relevant laws or regulations of such jurisdiction.

The offer presented in this press release is addressed only to people in member states of the European Economic Area (the “EEE“) who are” qualified investors “within the meaning of Article 2 (e) of Regulation (EU) 2017/1129. In the United Kingdom, this press release is addressed exclusively to, and addressed exclusively to, persons who (i) have experience professional in matters relating to investments covered by Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order“) or (ii) are persons covered by Article 49 (2) (a) to (e) of the Order and other persons to whom it may be legally communicated (all such persons together are referred to as”relevant people“). These materials are intended only for, and intended only for, relevant persons and qualified investors and should not be influenced or invoked (i) in the United Kingdom, by persons who are not relevant persons or (ii) in any member state of the EEA, by people who are not qualified investors. Any investment or investment activity to which these materials refer is available only to, and any invitation, offer or agreement to subscribe, buy or acquire any securities referred to herein will be involved only with, in the UK, relevant people, and in any EEA member state, qualified investors.

This press release does not constitute, or form part of, any offer or solicitation of an offer to subscribe for any shares or other securities.

Paula Fonseca